@article{7e2b684f68844db48c2898635ce15686,
title = "Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study",
abstract = "Oral semaglutide is the first oral glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes, and showed significant benefits in glycaemic control and weight reduction versus active comparators in the PIONEER phase 3a randomized controlled trial programme. In this retrospective study, we present early data on the use of oral semaglutide in clinical practice, from the US IBM Explorys electronic health record database. In 782 patients prescribed oral semaglutide, 54.5% were women, and the mean age (SD) was 57.8 years (11.3); 66.0% of patients received their prescription from a primary care practitioner. Although prescribing information recommends increasing the dose to 7 mg after 30 days, 37.0% of patients received a prescription only for the initial 3 mg dose. Mean body mass index was 36.2 kg/m2 (7.6); mean HbA1c was 8.4% (1.8%). Mean HbA1c change from baseline to approximately 6 months after oral semaglutide initiation was −0.9% (95% CI: −1.1%; −0.6%), with greater reductions in patients with higher baseline HbA1c. These data indicate prevalent early adoption of oral semaglutide in primary care, show real-world improvements in glycaemic control, and identify potential treatment gaps.",
keywords = "GLP-1, antidiabetic drug, database research, glycaemic control, observational study, type 2 diabetes",
author = "Aroda, {Vanita R.} and Mads Faurby and S{\o}ren Lophaven and Josh Noone and Wolden, {Michael Lyng} and Ildiko Lingvay",
note = "Funding Information: The authors acknowledge the medical writing assistance of Caroline Freeman of Oxford PharmaGenesis, Oxford, UK (funded by Novo Nordisk A/S). Certain data used in this study were supplied by International Business Machines Corporation. Any analysis, interpretation or conclusion based on these data is solely that of the authors and not International Business Machines Corporation (IBM). This study was funded by Novo Nordisk A/S. Funding Information: V.R.A. has performed consultancy for Applied Therapeutics, Duke, Novo Nordisk, Pfizer and Sanofi, and has received research support via institutional contracts from Applied Therapeutics/Medpace, Eli Lilly, Premier/Fractyl, Novo Nordisk and Sanofi/Medpace. Her spouse has been employed at Janssen and Merck. M.F. is an employee and shareholder of Novo Nordisk A/S. S.L. is employed as a consultant by Novo Nordisk A/S. J.N. is an employee of Novo Nordisk. M.L.W. is an employee and shareholder of Novo Nordisk A/S. I.L. has received research funding, advisory/consulting fees and/or other support from AstraZeneca, Bayer, Boehringer Ingelheim, Duke CRI, Eli Lilly, GI Dynamics, Intercept, Intarcia, Janssen, Mannkind, Merck, Mylan, Novartis, Novo Nordisk, Pfizer, Sanofi, TARGETPharma, Valeritas and Zealand Pharma. Funding Information: The authors acknowledge the medical writing assistance of Caroline Freeman of Oxford PharmaGenesis, Oxford, UK (funded by Novo Nordisk A/S). Certain data used in this study were supplied by International Business Machines Corporation. Any analysis, interpretation or conclusion based on these data is solely that of the authors and not International Business Machines Corporation (IBM). This study was funded by Novo Nordisk A/S. Publisher Copyright: {\textcopyright} 2021 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.",
year = "2021",
month = sep,
doi = "10.1111/dom.14453",
language = "English (US)",
volume = "23",
pages = "2177--2182",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "9",
}